Vaxess Technologies lands $6m for microneedle vaccines

Vaxess Technologies said today that it won 2 grants from the Bill & Melinda Gates Foundation totalling up to $6 million for the development of inactivated polio and live attenuated measles rubella vaccines using the company’s Mimix sustained-release microneedle patch technology.
The company’s Mimix technology is designed for sustained, transdermal delivery of vaccines and inmmunotherapies, according to Vaxess. The company engineered biopolymer microneedles to encapsulate antigens for controlled, transdermal administration and claims that the technology enhances efficacy, simplifies dosing and improves product stability under harsh environmental conditions.
Get the full story at our sister site, Drug Delivery Business News.
The post Vaxess Technologies lands $6m for microneedle vaccines appeared first on MassDevice.

Source: Mass Device - March 6, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Research & Development Wall Street Beat Vaxess Technologies Source Type: news